-
公开(公告)号：US11179384B2
公开(公告)日：2021-11-23
申请号：US16328620
申请日：2017-08-25
申请人： TAKEDA GMBH
IPC分类号： A61K31/473 , A61P3/10 , A61P1/16 , A61P3/06
摘要： The present invention is directed to methods for the treatment of non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steato-hepatitis (NASH) with a phosphodiesterase 4 (PDE4) inhibitor.
-
公开(公告)号：US11173208B2
公开(公告)日：2021-11-16
申请号：US15307214
申请日：2015-05-04
申请人： Takeda GmbH
发明人： Willow Diluzio , Phuong Nguyen
IPC分类号： A61K39/395 , A61K47/26 , A61K9/08 , C07K16/24 , A61K47/10 , A61K38/00 , A61K47/18 , A61K47/22
摘要： The present invention relates to aqueous formulations comprising a compound neutralizing GM-CSF in concentrations of at least 20 mg/ml, a tonicity modifier, a buffer and one or more of surfactants, amino acids, antioxidants and/or chelators, wherein the composition is stable. The ingredients of the formulation preferably provide stability to the compound neutralizing GM-CSF in view of long-term storage. In a preferred aspect, the formulation is for use in therapy, preferably for use in the treatment of inflammatory and autoimmune disorders, preferably including allergic and psoriatic disorders, as well as arthritic and asthmatic disorders.
-
公开(公告)号：US20210283122A1
公开(公告)日：2021-09-16
申请号：US16328620
申请日：2017-08-25
申请人： TAKEDA GMBH
IPC分类号： A61K31/473 , A61P3/06 , A61P1/16 , A61P3/10
摘要： The present invention is directed to methods for the treatment of non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steato-hepatitis (NASH) with a phosphodiesterase 4 (PDE4) inhibitor.
-
公开(公告)号：US20210121510A1
公开(公告)日：2021-04-29
申请号：US17047611
申请日：2019-04-17
摘要： The present invention relates to a bacteriophage composition comprising at least one bacteriophage species, at least one α-linked polymeric glucose and at least one polyol. In certain embodiments, the α-linked polymeric glucose has a mean molecular weight of greater than 10 kDa.
-
公开(公告)号：US09545490B2
公开(公告)日：2017-01-17
申请号：US14547891
申请日：2014-11-19
申请人： Takeda GmbH
发明人： Peter Iwatschenko , Gerhard Pohlmann , Horst Windt , Wolfgang Koch , Michel Kist
IPC分类号： A61M11/02 , A61M15/00 , A61M16/00 , A61M11/06 , A61M16/20 , A61M16/10 , A61M16/06 , A61M16/08 , A61M11/00 , B05B7/14
CPC分类号： A61M16/0069 , A61M11/001 , A61M11/02 , A61M11/06 , A61M15/0005 , A61M15/0006 , A61M15/0021 , A61M15/0065 , A61M15/0085 , A61M15/0086 , A61M16/0003 , A61M16/0666 , A61M16/0808 , A61M16/0833 , A61M16/085 , A61M16/1005 , A61M16/1065 , A61M16/107 , A61M16/202 , A61M16/208 , A61M2016/003 , A61M2016/1025 , A61M2202/064 , A61M2205/07 , A61M2205/3334 , A61M2205/42 , A61M2240/00 , B05B7/1413 , B05B7/1422
摘要： The claimed subject matter relates to a device for dosing and aerosolization of aerosolizable material. The device includes a body with an aerosolization channel with a distal attachment for connecting a source of carrier gas. The carrier gas provides pressure pulses to the aerosolization channel. A proximal attachment allows the aerosolized material to move to a reservoir for receiving the aerosolizable material. The reservoir is connected to the body via the the aerosolization channel. At least part of the walls of the device are self-exciting membranes that can be put into oscillation by the pressure pulses.
摘要翻译： 所要求保护的主题涉及可雾化材料的计量和雾化装置。 该装置包括具有雾化通道的主体，其具有用于连接载气源的远端附件。 载气向雾化通道提供压力脉冲。 近端附件允许气雾化材料移动到用于接收可雾化材料的储存器。 储存器通过雾化通道连接到身体。 装置的壁的至少一部分是自激振膜，可通过压力脉冲进入振荡。
-
公开(公告)号：US09090597B2
公开(公告)日：2015-07-28
申请号：US14473338
申请日：2014-08-29
申请人： TAKEDA GMBH
发明人： Beate Schmidt , Christian Scheufler , Jürgen Volz , Martin Feth , Rolf-Peter Hummel , Armin Hatzelmann , Christof Zitt , Andrea Wohlsen , Degenhard Marx , Hans-Peter Kley , Deborah Ockert , Anke Heuser , Johannes A. M. Christiaans , Geert Jan Sterk , Wiro M. P. B. Menge
IPC分类号： C07D401/14 , A61K31/4152
CPC分类号： C07D401/14 , A61K31/4152
摘要： The compound 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione is a novel effective inhibitor of the type 4 phosphodiesterase useful in the treatment of psoriasis or atopic dermatitis.
摘要翻译： 化合物1-（2- {4- [3-（3,4-二甲氧基苯基）-4,4-二甲基-5-氧代-4,5-二氢-1H-吡唑-1-基]哌啶-1-基 } -2-氧代乙基）吡咯烷-2,5-二酮是用于治疗牛皮癣或特应性皮炎的4型磷酸二酯酶的新型有效抑制剂。
-
公开(公告)号：US20150080400A1
公开(公告)日：2015-03-19
申请号：US14397319
申请日：2013-04-30
申请人： TAKEDA GMBH
发明人： Angelika Hoffmeyer , Rainer Boer , Manuela Hessmann , Andreas Pahl , Torsten Dunkern , Simone Hartung , Christof Zitt , Jurgen Volz , Christiane Praechter , Mahindra Makhija , Hiteshkumar Jain , Sandip Gavade , Arati Prabhu , Manojkumar Tiwari , Ashish Keche , Sarvesh Patel
IPC分类号： C07C233/81 , C07D295/155 , C07C271/42 , C07C237/52 , A61K31/27 , A61K31/495 , A61K31/4453 , A61K31/196 , A61K45/06 , C07C235/66 , A61K31/5375
CPC分类号： C07C233/81 , A61K31/196 , A61K31/27 , A61K31/4453 , A61K31/495 , A61K31/5375 , A61K45/06 , C07C233/75 , C07C235/66 , C07C237/40 , C07C237/42 , C07C237/52 , C07C271/42 , C07D295/155
摘要： The compounds of formula (1) in which R1, R4, A and X have the meanings as given in the description, are novel effective EP2 agonists.
摘要翻译： 其中R1，R4，A和X具有说明书中给出的含义的式（1）化合物是新型有效的EP2激动剂。
-
公开(公告)号：US08865745B2
公开(公告)日：2014-10-21
申请号：US13618026
申请日：2012-09-14
申请人： Beate Schmidt , Christian Scheufler , Juergen Volz , Martin Feth , Rolf-Peter Hummel , Armin Hatzelmann , Christof Zitt , Andrea Wohlsen , Degenhard Marx , Hans-Peter Kley , Deborah Ockert , Anke Heuser , Johannes A. M. Christiaans , Geert Jan Sterk , Wiro M. P. B. Menge
发明人： Beate Schmidt , Christian Scheufler , Juergen Volz , Martin Feth , Rolf-Peter Hummel , Armin Hatzelmann , Christof Zitt , Andrea Wohlsen , Degenhard Marx , Hans-Peter Kley , Deborah Ockert , Anke Heuser , Johannes A. M. Christiaans , Geert Jan Sterk , Wiro M. P. B. Menge
IPC分类号： A01N43/40 , A61K31/445 , C07D401/00 , C07D401/14
CPC分类号： C07D401/14 , A61K31/4152
摘要： The compound 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione is a novel effective inhibitor of the type 4 phosphodiesterase.
摘要翻译： 化合物1-（2- {4- [3-（3,4-二甲氧基苯基）-4,4-二甲基-5-氧代-4,5-二氢-1H-吡唑-1-基]哌啶-1-基 } -2-氧代乙基）吡咯烷-2,5-二酮是4型磷酸二酯酶的新型有效抑制剂。
-
公开(公告)号：US20140271636A1
公开(公告)日：2014-09-18
申请号：US14215816
申请日：2014-03-17
申请人： Takeda GmbH
发明人： Markus RAST , Wolfgang ISE , Gerhard BECKER , Peter SKUFCA , Henning GIESELER
CPC分类号： A61K9/19 , C07K16/2887 , C07K2317/24
摘要： The present invention provides a method for preparation of a lyophilized formulation of an anti-CD 20 antibody as well as to a lyophilized formulation of an anti-CD 20 antibody, comprising an anti-CD 20 antibody and having a residual moisture content in the range of 1% to 10%. The present invention also relates to the reconstituted formulation obtained by the method described herein, the use of said antibody formulation as a medicament, the use of the lyophilized formulation for the preparation of a medicament and a method of treating a patient.
摘要翻译： 本发明提供了制备抗CD20抗体的冻干制剂的方法以及抗CD 20抗体的冻干制剂，其包含抗CD 20抗体并且具有在该范围内的残留水分含量 为1％至10％。 本发明还涉及通过本文所述的方法获得的重建制剂，所述抗体制剂作为药物的用途，所述冻干制剂在制备药物中的用途以及治疗患者的方法。
-
10.发明申请PHARMACEUTICAL AEROSOL PRODUCT FOR ADMINISTRATION BY ORAL OR NASAL INHALATION 审中-公开用于口腔或鼻腔吸入管理的药物航空产品公开(公告)号：US20140170081A1
公开(公告)日：2014-06-19
申请号：US14238055
申请日：2012-08-13
CPC分类号： A61K9/124 , A61K9/008 , A61K31/58 , A61M11/04 , A61M15/0001 , A61M15/0065 , A61M15/009
摘要： The inventive subject matter relates to a pharmaceutical aerosol product suitable for administration by oral or nasal inhalation and its use in the treatment of respiratory diseases, in particular in the treatment of children.
摘要翻译： 本发明涉及适于通过口服或鼻吸入给药的药物气溶胶产品及其用于治疗呼吸系统疾病，特别是用于治疗儿童的呼吸系统疾病。
-
-
-
-
-
-
-
-
-
搜索结果
67 条记录 (耗时 0.039 秒)
